1.94
0.09 (4.86%)
| Penutupan Terdahulu | 1.85 |
| Buka | 1.91 |
| Jumlah Dagangan | 320,762 |
| Purata Dagangan (3B) | 49,850 |
| Modal Pasaran | 18,025,898 |
| Harga / Buku (P/B) | 0.790 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Aug 2025 - 11 Aug 2025 |
| Margin Operasi (TTM) | -11,193.25% |
| EPS Cair (TTM) | -3.70 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -62.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 31.69% |
| Nisbah Semasa (MRQ) | 1.69 |
| Aliran Tunai Operasi (OCF TTM) | -31.34 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -19.08 M |
| Pulangan Atas Aset (ROA TTM) | -48.28% |
| Pulangan Atas Ekuiti (ROE TTM) | -92.35% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | SAB Biotherapeutics, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | 0.5 |
| Purata | 0.75 |
|
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 21.02% |
| % Dimiliki oleh Institusi | 23.99% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| First Premier Bank | 31 Dec 2024 | 18,986 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 20.00 (Chardan Capital, 930.93%) | Beli |
| Median | 15.00 (673.20%) | |
| Rendah | 10.00 (HC Wainwright & Co., 415.46%) | Beli |
| Purata | 15.00 (673.20%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 1.90 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Chardan Capital | 15 May 2025 | 20.00 (930.93%) | Beli | 1.94 |
| 01 Apr 2025 | 20.00 (930.93%) | Beli | 1.23 | |
| HC Wainwright & Co. | 14 May 2025 | 10.00 (415.46%) | Beli | 1.85 |
| 01 Apr 2025 | 6.00 (209.28%) | Beli | 1.23 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 09 May 2025 | Pengumuman | SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates |
| 31 Mar 2025 | Pengumuman | SAB BIO Reports Full Year 2024 Operating and Financial Results |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |